Ubiquitin-proteasome system stress sensitizes ovarian cancer to proteasome inhibitor-induced apoptosis

被引:113
作者
Bazzaro, M
Lee, MK
Zoso, A
Stirling, WLH
Santillan, A
Shih, IE
Roden, RBS
机构
[1] Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD 21231 USA
[2] Johns Hopkins Univ, Sch Med, Dept Obstet & Gynecol, Baltimore, MD 21231 USA
[3] Johns Hopkins Univ, Sch Med, Dept Oncol, Baltimore, MD 21231 USA
关键词
D O I
10.1158/0008-5472.CAN-05-2321
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The ubiquitin-proteasome system (UPS) mediates targeted protein degradation. Notably, the UPS determines levels of key checkpoint proteins controlling apoptosis and proliferation by controlling protein half-life. Herein, we show that ovarian carcinoma manifests an overstressed UPS by comparison with normal tissues by accumulation of ubiquitinated proteins despite elevated proteasome levels. Elevated levels of total ubiquitinated proteins and 19S and 20S proteasome subunits are evident in both low-grade and high-grade ovarian carcinoma tissues relative to benign ovarian tumors and in ovarian carcinoma cell lines relative to immortalized surface epithelium. We find that ovarian carcinoma cell lines exhibit greater sensitivity to apoptosis in response to proteasome inhibitors than immortalized ovarian surface epithelial cells. This sensitivity correlates with increased cellular proliferation rate and UPS stress rather than absolute proteasome levels. Proteasomal inhibition in vitro induces cell cycle arrest and the accumulation of p21 and p27 and triggers apoptosis via activation of caspase-3. Furthermore, treatment with the licensed proteasome inhibitor PS-341 slows the growth of ES-2 ovarian carcinoma xenograft in immunodeficient mice. In sum, elevated proliferation and metabolic rate resulting from malignant transformation of the epithelium stresses the UPS and renders ovarian carcinoma more sensitive to apoptosis in response to proteasomal inhibition.
引用
收藏
页码:3754 / 3763
页数:10
相关论文
共 52 条
[1]  
Adams J, 1999, CANCER RES, V59, P2615
[2]   Development of the proteasome inhihitor Veleade™ (Bortezomib) [J].
Adams, J ;
Kauffman, M .
CANCER INVESTIGATION, 2004, 22 (02) :304-311
[3]  
Aghajanian C, 2002, CLIN CANCER RES, V8, P2505
[4]   Clinical update: Novel targets in gynecologic malignancies [J].
Aghajanian, C .
SEMINARS IN ONCOLOGY, 2004, 31 (06) :22-26
[5]   The proteasome:: Paradigm of a self-compartmentalizing protease [J].
Baumeister, W ;
Walz, J ;
Zühl, F ;
Seemuller, E .
CELL, 1998, 92 (03) :367-380
[6]   Impairment of the ubiquitin-proteasome system by protein aggregation [J].
Bence, NF ;
Sampat, RM ;
Kopito, RR .
SCIENCE, 2001, 292 (5521) :1552-1555
[7]   THE UBIQUITIN-PROTEASOME PROTEOLYTIC PATHWAY [J].
CIECHANOVER, A .
CELL, 1994, 79 (01) :13-21
[8]   The ubiquitin-proteasome pathway: on protein death and cell life [J].
Ciechanover, A .
EMBO JOURNAL, 1998, 17 (24) :7151-7160
[9]   N-terminal ubiquitination of extracellular signal-regulated kinase 3 and p21 directs their degradation by the proteasome [J].
Coulombe, P ;
Rodier, G ;
Bonneil, E ;
Thibault, P ;
Meloche, S .
MOLECULAR AND CELLULAR BIOLOGY, 2004, 24 (14) :6140-6150
[10]   Inhibition of proteasome function induces programmes cell death in proliferating endothelial cells [J].
Drexler, HCA ;
Risau, W ;
Konerding, MA .
FASEB JOURNAL, 2000, 14 (01) :65-77